Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44


CD73 expression and clinical significance in human metastatic melanoma.

Monteiro I, Vigano S, Faouzi M, Treilleux I, Michielin O, Ménétrier-Caux C, Caux C, Romero P, de Leval L.

Oncotarget. 2018 Jun 1;9(42):26659-26669. doi: 10.18632/oncotarget.25426. eCollection 2018 Jun 1.


Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints.

Gourdin N, Bossennec M, Rodriguez C, Vigano S, Machon C, Jandus C, Bauché D, Faget J, Durand I, Chopin N, Tredan O, Marie JC, Dubois B, Guitton J, Romero P, Caux C, Ménétrier-Caux C.

Cancer Res. 2018 Jul 1;78(13):3604-3618. doi: 10.1158/0008-5472.CAN-17-2405. Epub 2018 Mar 20.


ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, E Heudel P, Cassier P, Chabaud S, Croughs T, Dupont P, C Cadore A, Clapisson G, Delgado A, Bardin-Dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2018 Feb 1;29(2):523. doi: 10.1093/annonc/mdx058. No abstract available.


A Milestone Review on How Macrophages Affect Tumor Growth.

Caux C, Ramos RN, Prendergast GC, Bendriss-Vermare N, Ménétrier-Caux C.

Cancer Res. 2016 Nov 15;76(22):6439-6442. doi: 10.1158/0008-5472.CAN-16-2631. No abstract available.


Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.

Le KS, Thibult ML, Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, Broussais F, Bouabdallah R, Colisson R, Caux C, Ménétrier-Caux C, Leroux D, Xerri L, Olive D.

Cancer Res. 2016 Aug 15;76(16):4648-60. doi: 10.1158/0008-5472.CAN-15-0589. Epub 2016 May 31.


Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay.

Verronèse E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, Ray-Coquard I, Bachelot T, N'Kodia A, Bardin-Dit-Courageot C, Rigal C, Pérol D, Caux C, Ménétrier-Caux C.

Oncoimmunology. 2015 Nov 10;5(3):e1100791. eCollection 2016 Mar.


ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2015 Jul;26(7):1353-62. doi: 10.1093/annonc/mdv173. Epub 2015 Apr 7.


PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity.

Mathieu AL, Verronese E, Rice GI, Fouyssac F, Bertrand Y, Picard C, Chansel M, Walter JE, Notarangelo LD, Butte MJ, Nadeau KC, Csomos K, Chen DJ, Chen K, Delgado A, Rigal C, Bardin C, Schuetz C, Moshous D, Reumaux H, Plenat F, Phan A, Zabot MT, Balme B, Viel S, Bienvenu J, Cochat P, van der Burg M, Caux C, Kemp EH, Rouvet I, Malcus C, Méritet JF, Lim A, Crow YJ, Fabien N, Ménétrier-Caux C, De Villartay JP, Walzer T, Belot A.

J Allergy Clin Immunol. 2015 Jun;135(6):1578-88.e5. doi: 10.1016/j.jaci.2015.01.040. Epub 2015 Apr 2.


Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response.

Chapellier M, Bachelard-Cascales E, Schmidt X, Clément F, Treilleux I, Delay E, Jammot A, Ménétrier-Caux C, Pochon G, Besançon R, Voeltzel T, Caron de Fromentel C, Caux C, Blay JY, Iggo R, Maguer-Satta V.

Stem Cell Reports. 2015 Feb 10;4(2):239-54. doi: 10.1016/j.stemcr.2014.12.007. Epub 2015 Jan 15.


ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+ T cells by plasmacytoid dendritic cells.

Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Ménétrier-Caux C.

Oncoimmunology. 2013 Mar 1;2(3):e23185.


Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.

Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, Bendriss-Vermare N.

Int J Cancer. 2013 Aug 1;133(3):771-8. doi: 10.1002/ijc.28072. Epub 2013 Mar 8.


Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.

Trédan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Ménétrier-Caux C.

Eur J Cancer. 2013 May;49(7):1673-82. doi: 10.1016/j.ejca.2012.11.028. Epub 2012 Dec 19.


CD4 lymphopenia to identify end-of-life metastatic cancer patients.

Péron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Menetrier-Caux C, Blay JY.

Eur J Cancer. 2013 Mar;49(5):1080-9. doi: 10.1016/j.ejca.2012.11.003. Epub 2012 Dec 13.


ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.

Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, Bachelot T, Treilleux I, Goddard-Leon S, Lavergne E, Chabaud S, Blay JY, Caux C, Ménétrier-Caux C.

Cancer Res. 2012 Dec 1;72(23):6130-41. doi: 10.1158/0008-5472.CAN-12-2409. Epub 2012 Oct 1.


Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment.

Ménétrier-Caux C, Faget J, Biota C, Gobert M, Blay JY, Caux C.

Oncoimmunology. 2012 Aug 1;1(5):759-761.


Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier-Caux C, Caux C, Bendriss-Vermare N.

Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25.


Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.

Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Ménétrier-Caux C.

Oncoimmunology. 2012 Jul 1;1(4):432-440.


Targeting regulatory T cells.

Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W.

Target Oncol. 2012 Mar;7(1):15-28. doi: 10.1007/s11523-012-0208-y. Epub 2012 Feb 12. Review.


Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells.

Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, Goutagny N, Durand I, Léon-Goddard S, Blay JY, Caux C, Ménétrier-Caux C.

Cancer Res. 2011 Oct 1;71(19):6143-52. doi: 10.1158/0008-5472.CAN-11-0573. Epub 2011 Aug 18.


Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.

Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, Tredan O, Durand I, Ménétrier-Caux C, Caux C, Blay JY, Ray-Coquard I, Bendriss-Vermare N.

Cancer Res. 2011 Aug 15;71(16):5423-34. doi: 10.1158/0008-5472.CAN-11-0367. Epub 2011 Jun 22.


Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer.

Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Ménétrier-Caux C, Trédan O, Goddard-Léon S, Pin JJ, Mignotte H, Bathélémy-Dubois C, Caux C, Lebecque S, Blay JY.

BMC Cancer. 2011 May 30;11:213. doi: 10.1186/1471-2407-11-213.


C/EBP{delta} and STAT-1 are required for TLR8 transcriptional activity.

Zannetti C, Bonnay F, Takeshita F, Parroche P, Ménétrier-Caux C, Tommasino M, Hasan UA.

J Biol Chem. 2010 Nov 5;285(45):34773-80. doi: 10.1074/jbc.M110.133884. Epub 2010 Sep 9.


Differences in tumor regulatory T-cell localization and activation status impact patient outcome.

Ménétrier-Caux C, Gobert M, Caux C.

Cancer Res. 2009 Oct 15;69(20):7895-8. doi: 10.1158/0008-5472.CAN-09-1642. Epub 2009 Oct 6. Review.


Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival.

Labidi SI, Ménétrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T, Biron P, Blay JY, Ghesquières H.

Ann Hematol. 2010 Jan;89(1):25-33. doi: 10.1007/s00277-009-0777-8. Epub 2009 Jul 7.


Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY, Ménétrier-Caux C.

Cancer Res. 2009 Mar 1;69(5):2000-9. doi: 10.1158/0008-5472.CAN-08-2360. Epub 2009 Feb 24.


Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs.

Hasan UA, Caux C, Perrot I, Doffin AC, Menetrier-Caux C, Trinchieri G, Tommasino M, Vlach J.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8047-52. Epub 2007 Apr 26.


Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases.

Evrard S, Menetrier-Caux C, Biota C, Neaud V, Mathoulin-Pélissier S, Blay JY, Rosenbaum J.

Gastroenterol Clin Biol. 2007 Feb;31(2):141-5.


Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome.

Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F.

Br J Cancer. 2006 Apr 10;94(7):1066-70.


Insulin-Like Growth Factor (IGF) family and prostate cancer.

Gennigens C, Menetrier-Caux C, Droz JP.

Crit Rev Oncol Hematol. 2006 May;58(2):124-45. Epub 2006 Jan 18. Review.


CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.

Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P, Blay JY.

Cancer. 2004 Dec 1;101(11):2675-80.


IL-6 as an intracrine growth factor for renal carcinoma cell lines.

Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY.

Int J Cancer. 2004 Sep 20;111(5):653-61.


Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.

Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY; Groupe Francais d'Immunotherapie.

J Clin Oncol. 2004 Jun 15;22(12):2371-8. Erratum in: J Clin Oncol. 2004 Nov 15;22(22):4656. Pallardy, Michel [corrected to Pallardy, Marc].


OSCAR is an FcRgamma-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of human dendritic cells.

Merck E, Gaillard C, Gorman DM, Montero-Julian F, Durand I, Zurawski SM, Menetrier-Caux C, Carra G, Lebecque S, Trinchieri G, Bates EE.

Blood. 2004 Sep 1;104(5):1386-95. Epub 2004 May 20.


Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes.

Thomachot MC, Bendriss-Vermare N, Massacrier C, Biota C, Treilleux I, Goddard S, Caux C, Bachelot T, Blay JY, Menetrier-Caux C.

Int J Cancer. 2004 Jul 10;110(5):710-20.


Long-lived immature dendritic cells mediated by TRANCE-RANK interaction.

Cremer I, Dieu-Nosjean MC, Maréchal S, Dezutter-Dambuyant C, Goddard S, Adams D, Winter N, Menetrier-Caux C, Sautès-Fridman C, Fridman WH, Mueller CG.

Blood. 2002 Nov 15;100(10):3646-55. Epub 2002 Jul 5.


IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.

Menetrier-Caux C, Thomachot MC, Alberti L, Montmain G, Blay JY.

Cancer Res. 2001 Apr 1;61(7):3096-104.


[Cancer immunotherapy: new approaches].

Blay JY, Thomachot MC, Alberti L, Bachelot T, Voorzanger-Rousselot N, Puisieux I, Odin L, Ménétrier-Caux C.

Bull Cancer. 2000 Jan;87(1):97-106. Review. French. No abstract available.


Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes.

Ménétrier-Caux C, Bain C, Favrot MC, Duc A, Blay JY.

Br J Cancer. 1999 Jan;79(1):119-30.


Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.

Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M.

Int J Cancer. 1997 Jul 29;72(3):424-30.


Identification of human IgG autoantibodies specific for IL-10.

Menetrier-Caux C, Briere F, Jouvenne P, Peyron E, Peyron F, Banchereau J.

Clin Exp Immunol. 1996 Apr;104(1):173-9.


Immunologic and biochemical alterations in severe falciparum malaria: relation to neurological symptoms and outcome.

Deloron P, Dumont N, Nyongabo T, Aubry P, Astagneau P, Ndarugirire F, Menetrier-Caux C, Burdin N, Brelivet JC, Peyron F.

Clin Infect Dis. 1994 Sep;19(3):480-5.


Supplemental Content

Loading ...
Support Center